Earlier this summer, the U.S. Supreme Court handed Big Pharma a big victory. In Bristol-Myers Squibb Co. v. Superior Court of California, the high court struck down California’s effort to widen the scope of non-residents seeking relief from dangerous drugs.
In an 8-1 decision, the court ruled against nearly 680 plaintiffs who were suing the pharmaceutical giant over the blood-clotting drug Plavix. The vast majority of the plaintiffs lived outside of the state, so the drug company challenged their ability to file suit in California.
Burg Simpson founding shareholder and Colorado commercial attorney Michael S. Burg decried the decision as a loss for the little guy in a column on Stat, a health and medicine news site.
“The Supreme Court’s ruling in favor of BMS is a staggering blow for millions of Americans harmed each year by the reckless and abusive behavior of pharmaceutical companies,” Michael explained. “The decision raises an almost insurmountably high hurdle between victims and their hopes for obtaining justice in state courts throughout the country.”
You can read Michael’s entire opinion on this case here.